Comparative Pharmacology
Head-to-head clinical analysis: REMICADE versus SIMLANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REMICADE versus SIMLANDI.
REMICADE vs SIMLANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Infliximab is a chimeric monoclonal IgG1 antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory cytokine activity by preventing its interaction with p55 and p75 cell surface TNF receptors.
SIMLANDI (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, thereby reducing inflammatory responses.
5 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks thereafter; for rheumatoid arthritis, may increase to 10 mg/kg every 8 weeks if needed.
Subcutaneous injection, 40 mg every 2 weeks; may increase to 40 mg weekly if no response within 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 7.7 to 9.5 days (range 7-12 days). The prolonged half-life supports every-8-week dosing; may be shorter in patients with high tumor burden or immunogenicity.
Terminal elimination half-life is approximately 14 days (range 10–20 days) in patients with rheumatoid arthritis; this supports a subcutaneous dosing interval of every other week.
Infliximab is eliminated primarily via the reticuloendothelial system. No significant renal or biliary excretion; less than 0.1% of dose excreted unchanged in urine. Clearance is mainly through proteolytic catabolism.
Adalimumab is eliminated primarily via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion of intact drug is minimal.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor